Research shows biological clocks could improve brain cancer treatment

January 10, 2018, Texas A&M University
Neurospora crassa samples growing in Bell-Pedersen's Center for Biological Clocks Research laboratory. The bands in the tubes indicate the daily rhythm of spore formation in the fungus. Credit: Texas A&M University

Biological clocks throughout the body play a major role in human health and performance, from sleep and energy use to how food is metabolized and even stroke severity. Now, Texas A&M University researchers found that circadian rhythms could hold the key to novel therapies for glioblastoma, the most prevalent type of brain cancer in adults—and one with a grim prognosis.

Scientists in the Texas A&M Center for Biological Clocks Research (CBCR) determined that the timed production of a particular protein, associated with tumor proliferation and growth, is disrupted in , and they believe that this may lead to a more effective technique to treat the cancerous cells without damaging the healthy surrounding tissue. These findings, which were supported in part by the National Institutes of Health, were published today (Jan. 10) in the international journal BMC Cancer.

Texas A&M biologist Deborah Bell-Pedersen, PhD, a co-corresponding author on the study, found in her previous research that the biological clock in the model fungal system Neurospora crassa controls daily rhythms in the activity of a signaling molecule, called p38 mitogen activated protein kinase (MAPK). This signaling protein plays a role in glioblastoma's highly invasive and aggressive properties.

In the new research, David J. Earnest, PhD, a mammalian biological clocks expert at the Texas A&M College of Medicine and co-corresponding author on the study, collaborated with Bell-Pedersen to show that the clock controls daily rhythms in p38 MAPK activity in a variety of as well, including normal glial cells, the supporting "helper" cells surrounding neurons.

Furthermore, their work found that such regulation is absent in glioblastoma cells. "We tested to see if inhibition of this cancer-promoting protein in glioblastoma cells would alter their invasive properties," said Bell-Pedersen, an internationally recognized leader in the fields of circadian and fungal biology. "Indeed, we found that inhibition of p38 MAPK at specific times of the day—times when the activity is low in normal glial cells under control of the circadian clock—significantly reduced glioblastoma cell invasiveness to the level of noninvasive glioma cells."

These findings indicate that glioblastoma might be a good candidate for chronochemotherapy, meaning treating cancer at specific times of day to get the most impact.

"Chronotherapeutic strategies have had a significant positive impact on the treatment of many types of cancer by optimizing the specific timing of drug administration to improve the efficacy and reduce the toxicity of chemotherapy," Bell-Pedersen said. "However, circadian biology has not been applied to the development of chronotherapeutic strategies for the treatment of glioblastoma, and clinical outcomes for this common primary brain tumor have shown limited improvement over the past 30 years."

Glioblastomas gained some attention this summer when Senator John McCain was diagnosed with the condition. "A big reason for poor prognosis for patients with this aggressive type of tumor is that the glioblastoma cells rapidly and unabatedly invade and disrupt the surrounding brain cells," said Gerard Toussaint, MD, a clinician and assistant professor at the Texas A&M College of Medicine who specializes in glioblastoma. Current treatments—including chemotherapy, surgical resection, immunotherapy and radiation—are largely ineffective in prolonging life expectancy beyond 18 months.

"We found that an inhibitor of p38 MAPK activity would make the cells behave less invasively, and if you can control the invasive properties, you can improve prognosis," Earnest said. In addition, the team's data indicate such treatment may be more effective and less toxic if administered at the appropriate time of the day.

This reduced toxicity is important, because a drug to inhibit the cancer-promoting activity of this protein was tested but found to be too harmful, with too many side effects. "If treatment with the drug can be timed to when the normal glial cells naturally have low activity of p38 MAPK, the addition of the drug might not be as toxic for these , and yet would still be very effective on the ," Earnest said.

Although promising, the current studies were done using cell cultures. The team's next step is to test p38 inhibitor chronochemotherapy in an animal model for . If successful, they would then move on to clinical trials.

"We work on a model system, and the reason to do that is that we can make progress quickly, and we always hope that what we're working on will lead to something useful, and I think this is a prime example of how putting effort into basic research can pay off," Bell-Pedersen said. "We're very hopeful and encouraged by our data that we'll find a treatment."

Explore further: Identification of PTPRZ as a drug target for cancer stem cells in glioblastoma

More information: Charles S. Goldsmith et al, Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness, BMC Cancer (2018). DOI: 10.1186/s12885-017-3896-y

Related Stories

Identification of PTPRZ as a drug target for cancer stem cells in glioblastoma

July 19, 2017
Glioblastoma is a malignant brain tumor with high mortality. Cancer stem cells are thought to be crucial for tumor initiation and its recurrence after standard therapy with radiation and temozolomide (TMZ) chemotherapy. Protein ...

Glioblastoma survival mechanism reveals new therapeutic target

December 11, 2017
A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation ...

Vulnerability identified for subtypes of glioblastoma

November 30, 2017
Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University ...

Using a microRNA to shift the makeup of glioblastoma subtypes

July 13, 2017
Glioblastoma multiforme (GBM), an extremely aggressive brain cancer, is a very complex disease. It is characterized by a fast-growing tumor in the brain composed of many subpopulations of cells, including glioblastoma stem ...

Onalespib could be an effective treatment for glioblastoma, preclinical studies show

November 2, 2017
The targeted therapy onalespib has shown effectiveness in preclinical studies of glioblastoma by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove ...

Inhibiting a DNA-repairing protein in brain could be key to treating aggressive tumors

January 10, 2017
Targeting a specific DNA-repairing protein in the brain could be an effective way to treat the most aggressive type of brain tumour, a study suggests.

Recommended for you

New breath and urine tests detect early breast cancer more accurately

April 25, 2018
A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.

Do prostate cancer cells have an Achilles' heel?

April 25, 2018
Researchers at the University of Illinois at Chicago describe new ways to selectively kill prostate cancer cells by exploiting the cells' revved-up metabolism. They report their findings in the online journal, eLife.

Research shows possible new target for immunotherapy for solid tumors

April 24, 2018
Research from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.

Changes in breast tissue increase cancer risk for older women

April 24, 2018
Researchers in Norway, Switzerland, and the United States have identified age-related differences in breast tissue that contribute to older women's increased risk of developing breast cancer. The findings, published April ...

Targeting molecules called miR-200s and ADAR2 could prevent tumor metastasis in patients with colorectal cancer

April 24, 2018
Colorectal cancer is the third most common cancer worldwide and the third-leading cause of cancer-related deaths. The main cause of death in patients with colorectal cancer is liver metastasis, with nearly 70% of patients ...

Experimental arthritis drug prevents stem cell transplant complication

April 24, 2018
An investigational drug in clinical trials for rheumatoid arthritis prevents a common, life-threatening side effect of stem cell transplants, new research from Washington University School of Medicine in St. Louis shows. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.